{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:09:12Z","timestamp":1794344952034,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03445-4","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:22:17Z","timestamp":1734513737000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of comparative efficacy of Umeclidinium\/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs"],"prefix":"10.1186","volume":"24","author":[{"given":"He","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"3445_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-med-080919-112707","volume":"72","author":"MC Ferrera","year":"2021","unstructured":"Ferrera MC, Labaki WW, Han MK. Advances in Chronic Obstructive Pulmonary Disease. Annu Rev Med. 2021;72:119\u201334. https:\/\/doi.org\/10.1146\/annurev-med-080919-112707","journal-title":"Annu Rev Med"},{"key":"3445_CR2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6824a1","author":"AG Wheaton","year":"2019","unstructured":"Wheaton AG, Liu Y, Croft JB, et al. MMWR Morb Mortal Wkly Rep. 2019;68(24):533\u20138. https:\/\/doi.org\/10.15585\/mmwr.mm6824a1. Chronic Obstructive Pulmonary Disease and Smoking Status - United States, 2017."},{"issue":"2","key":"3445_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-2005-869541","volume":"26","author":"MM Weder","year":"2005","unstructured":"Weder MM, Donohue JF. Role of bronchodilators in chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2005;26(2):221\u201334. https:\/\/doi.org\/10.1055\/s-2005-869541","journal-title":"Semin Respir Crit Care Med"},{"key":"3445_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2147\/COPD.S47792","volume":"9","author":"M Malerba","year":"2014","unstructured":"Malerba M, Morjaria JB, Radaeli A. Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD\u2013role of umeclidinium\/vilanterol. Int J Chron Obstruct Pulmon Dis. 2014;9:687\u201395. https:\/\/doi.org\/10.2147\/COPD.S47792","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3445_CR5","doi-asserted-by":"publisher","unstructured":"Brealey N, Gupta A, Renaux J, Mehta R, Allen A, Henderson A. Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers. Int J Clin Pharmacol Ther. 2015;53(9):753\u2009\u2013\u200964. doi: 10.5414\/CP202390. Erratum in: Int J Clin Pharmacol Ther. 2016;54(1):76\u201380. Erratum in: Int J Clin Pharmacol Ther. 2016;54(1):76\u201380. https:\/\/doi.org\/10.5414\/CPP54076","DOI":"10.5414\/CPP54076"},{"key":"3445_CR6","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2147\/JAA.S424055","volume":"16","author":"M Bogart","year":"2023","unstructured":"Bogart M, Germain G, Lalibert\u00e9 F, et al. Real-world study of Single-Inhaler Triple Therapy with Fluticasone Furoate\/Umeclidinium\/Vilanterol on Asthma Control in the US. J Asthma Allergy. 2023;16:1309\u201322. https:\/\/doi.org\/10.2147\/JAA.S424055","journal-title":"J Asthma Allergy"},{"issue":"1","key":"3445_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","volume":"21","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Brown N, Compton C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131. https:\/\/doi.org\/10.1186\/s12931-020-01360-w","journal-title":"Respir Res"},{"issue":"1","key":"3445_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1089\/jamp.2021.0061","volume":"36","author":"M Hamilton","year":"2023","unstructured":"Hamilton M, Anderson M, Dhand R, Patmore O, Prime D, Taylor E. Vitro Drug Deliveryfixed dosedcombinationnation of Fluticasone Furoate\/Umeclidinium\/Vilanterol fdry powderPinhalernhaler. J Aerosol Med Pulm Drug Deliv. 2023;36(1):34\u201343. https:\/\/doi.org\/10.1089\/jamp.2021.0061","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"4","key":"3445_CR9","doi-asserted-by":"publisher","first-page":"00061","DOI":"10.1183\/23120541.00061-2019","volume":"5","author":"S Worsley","year":"2019","unstructured":"Worsley S, Snowise N, Halpin DMG, et al. Clinical effectiveness of once-daily fluticasone furoate\/umeclidinium\/vilanterol in usual practice: the COPD INTREPID study design. ERJ Open Res. 2019;5(4):00061\u20132019. https:\/\/doi.org\/10.1183\/23120541.00061-2019","journal-title":"ERJ Open Res"},{"issue":"3","key":"3445_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4187\/respcare.10188","volume":"68","author":"K Ohtsuka","year":"2023","unstructured":"Ohtsuka K, Harada N, Horiuchi A, et al. Therapeutic response to single-inhaler Triple therapies in Moderate-to-severe COPD. Respir Care. 2023;68(3):330\u20137. https:\/\/doi.org\/10.4187\/respcare.10188","journal-title":"Respir Care"},{"issue":"3","key":"3445_CR11","doi-asserted-by":"publisher","first-page":"CD012930","DOI":"10.1002\/14651858.CD012930.pub2","volume":"3","author":"U Maqsood","year":"2019","unstructured":"Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):CD012930. https:\/\/doi.org\/10.1002\/14651858.CD012930.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"3445_CR12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/resp.12603","volume":"20","author":"N Horita","year":"2015","unstructured":"Horita N, Miyazawa N, Tomaru K, Inoue M, Kaneko T. Long-acting muscarinic antagonist\u2009+\u2009long-acting beta agonist versus long-acting beta agonist\u2009+\u2009inhaled corticosteroid for COPD: a systematic review and meta-analysis. Respirology. 2015;20(8):1153\u20139. https:\/\/doi.org\/10.1111\/resp.12603","journal-title":"Respirology"},{"issue":"6","key":"3445_CR13","doi-asserted-by":"publisher","first-page":"CD012066","DOI":"10.1002\/14651858.CD012066.pub3","volume":"6","author":"N Fukuda","year":"2023","unstructured":"Fukuda N, Horita N, Kaneko A, Goto A, Kaneko T, Ota E, Kew KM. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2023;6(6):CD012066. https:\/\/doi.org\/10.1002\/14651858.CD012066.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3445_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.pupt.2006.06.001","volume":"20","author":"M Cazzola","year":"2007","unstructured":"Cazzola M, And\u00f2 F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D\u2019Amato M. A pilot study to assess the effects of combining fluticasone propionate\/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. PulmPharmacol Ther. 2007;20(5):556\u201361. https:\/\/doi.org\/10.1016\/j.pupt.2006.06.001","journal-title":"PulmPharmacol Ther"},{"key":"3445_CR15","doi-asserted-by":"publisher","unstructured":"Lopez-Campos JL, Carrasco-Hernandez L, Quintana-Gallego E, et al. Triple therapy for COPD: a crude analysis from a systematic review of the evidence. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619885522. https:\/\/doi.org\/10.1177\/1753466619885522","DOI":"10.1177\/1753466619885522"},{"issue":"1","key":"3445_CR16","doi-asserted-by":"publisher","first-page":"e001607","DOI":"10.1136\/bmjresp-2022-001607","volume":"10","author":"K Takahashi","year":"2023","unstructured":"Takahashi K, Kawayama T, Takamori A, et al. TRACK (triple therapy for Japanese with mild to moderate COPD in Kyushu) study investigator group. Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study. BMJ Open Respir Res. 2023;10(1):e001607. https:\/\/doi.org\/10.1136\/bmjresp-2022-001607","journal-title":"BMJ Open Respir Res"},{"key":"3445_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/COPD.S114273","volume":"12","author":"C Lal","year":"2016","unstructured":"Lal C, Strange C. Spotlight on fluticasone furoate\/umeclidinium\/vilanterol in COPD: design, development, and potential place in therapy. Int J Chron Obstruct Pulmon Dis. 2016;12:135\u201340. https:\/\/doi.org\/10.2147\/COPD.S114273","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"2","key":"3445_CR18","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s41030-018-0057-7","volume":"4","author":"B Alc\u00e1zar Navarrete","year":"2018","unstructured":"Alc\u00e1zar Navarrete B, Boucot I, Naya I, et al. Umeclidinium\/Vilanterol Versus Tiotropium\/Olodaterol in Maintenance-Na\u00efve patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: a Post Hoc Analysis. Pulm Ther. 2018;4(2):171\u201383. https:\/\/doi.org\/10.1007\/s41030-018-0057-7","journal-title":"Pulm Ther"},{"key":"3445_CR19","doi-asserted-by":"publisher","unstructured":"Bansal S, Anderson M, Anzueto A et al. Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) triple therapy versus tiotropium monotherapy in patients with COPD. npj Prim Care Respir; 2021 Med 31, 29. https:\/\/doi.org\/10.1038\/s41533-021-00241-z","DOI":"10.1038\/s41533-021-00241-z"},{"issue":"1","key":"3445_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12931-018-0724-0","volume":"19","author":"PR Bremner","year":"2018","unstructured":"Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA. Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19. https:\/\/doi.org\/10.1186\/s12931-018-0724-0","journal-title":"Respir Res"},{"key":"3445_CR21","doi-asserted-by":"publisher","unstructured":"Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A. Once-daily umeclidinium\/vilanterol 125\/25 mcg in COPD: a randomized, controlled study. Chest. 2014; 145(5):981\u2013991. https:\/\/doi.org\/10.1378\/chest.13-1579. Erratum in: Chest. 2022; 162(1):269. doi: 10.1016\/j.chest.2022.05.026.","DOI":"10.1378\/chest.13-1579"},{"issue":"6","key":"3445_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472\u201386. https:\/\/doi.org\/10.1016\/S2213-2600(14)70065-7","journal-title":"Lancet Respir Med"},{"issue":"7","key":"3445_CR23","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.rmed.2015.04.018","volume":"109","author":"JF Donohue","year":"2015","unstructured":"Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870\u201381. https:\/\/doi.org\/10.1016\/j.rmed.2015.04.018","journal-title":"Respir Med"},{"issue":"11","key":"3445_CR24","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s12325-017-0626-4","volume":"34","author":"GJ Feldman","year":"2017","unstructured":"Feldman GJ, Sousa AR, Lipson DA, et al. Comparative efficacy of once-Daily Umeclidinium\/Vilanterol and Tiotropium\/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: a randomized study. Adv Ther. 2017;34(11):2518\u201333. https:\/\/doi.org\/10.1007\/s12325-017-0626-4","journal-title":"Adv Ther"},{"issue":"2","key":"3445_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40268-016-0131-2","volume":"16","author":"C Kalberg","year":"2016","unstructured":"Kalberg C, O\u2019Dell D, Galkin D, Newlands A, Fahy WA. Dual bronchodilator therapy with Umeclidinium\/Vilanterol versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: a Randomized Controlled Trial. Drugs R D. 2016;16(2):217\u201327. https:\/\/doi.org\/10.1007\/s40268-016-0131-2","journal-title":"Drugs R D"},{"key":"3445_CR26","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.2147\/COPD.S226601","volume":"14","author":"M Kato","year":"2019","unstructured":"Kato M, Tomii K, Hashimoto K, et al. The IMPACT study - single inhaler Triple Therapy (FF\/UMEC\/VI) versus FF\/VI and UMEC\/VI in patients with COPD: Efficacy and Safety in a Japanese Population. Int J Chron Obstruct Pulmon Dis. 2019;14:2849\u201361. https:\/\/doi.org\/10.2147\/COPD.S226601","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"3445_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00408-017-0055-9","volume":"195","author":"E Kerwin","year":"2017","unstructured":"Kerwin E, Ferguson GT, Sanjar S, et al. Dual bronchodilation with Indacaterol Maleate\/Glycopyrronium Bromide Compared with Umeclidinium Bromide\/Vilanterol in patients with moderate-to-severe COPD: results from two Randomized, Controlled, cross-over studies. Lung. 2017;195(6):739\u201347. https:\/\/doi.org\/10.1007\/s00408-017-0055-9","journal-title":"Lung"},{"issue":"18","key":"3445_CR28","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, et al. IMPACT investigators. Once-daily single-inhaler Triple versus Dual Therapy in patients with COPD. N Engl J Med. 2018;378(18):1671\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1713901","journal-title":"N Engl J Med"},{"issue":"12","key":"3445_CR29","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.rmed.2014.10.002","volume":"108","author":"MR Maleki-Yazdi","year":"2014","unstructured":"Maleki-Yazdi MR, Kaelin T, Richard N, Zvarich M, Church A. Efficacy and safety of umeclidinium\/vilanterol 62.5\/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752\u201360. https:\/\/doi.org\/10.1016\/j.rmed.2014.10.002","journal-title":"Respir Med"},{"issue":"9","key":"3445_CR30","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s12325-019-01015-3","volume":"36","author":"F Maltais","year":"2019","unstructured":"Maltais F, Ferguson GT, Feldman GJ, et al. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate\/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium\/Vilanterol Dry Powder Inhaler in COPD. Adv Ther. 2019;36(9):2434\u201349. https:\/\/doi.org\/10.1007\/s12325-019-01015-3","journal-title":"Adv Ther"},{"issue":"1","key":"3445_CR31","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","volume":"20","author":"F Maltais","year":"2019","unstructured":"Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238. https:\/\/doi.org\/10.1186\/s12931-019-1193-9","journal-title":"Respir Res"},{"issue":"1","key":"3445_CR32","doi-asserted-by":"publisher","first-page":"00073","DOI":"10.1183\/23120541.00073-2017","volume":"4","author":"JH Riley","year":"2018","unstructured":"Riley JH, Kalberg CJ, Donald A, Lipson DA, Shoaib M, Tombs L. Effects of umeclidinium\/vilanterol on exercise endurance in COPD: a randomised study. ERJ Open Res. 2018;4(1):00073\u20132017. https:\/\/doi.org\/10.1183\/23120541.00073-2017","journal-title":"ERJ Open Res"},{"key":"3445_CR33","doi-asserted-by":"publisher","first-page":"971","DOI":"10.2147\/COPD.S102962","volume":"11","author":"TM Siler","year":"2016","unstructured":"Siler TM, Donald AC, O\u2019Dell D, Church A, Fahy WA. A randomized, parallel-group study to evaluate the efficacy of umeclidinium\/vilanterol 62.5\/25 \u00b5g on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971\u20139. https:\/\/doi.org\/10.2147\/COPD.S102962","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3445_CR34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","volume":"15","author":"D Singh","year":"2015","unstructured":"Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91. https:\/\/doi.org\/10.1186\/s12890-015-0092-1","journal-title":"BMC Pulm Med"},{"key":"3445_CR35","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"3445_CR36","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"3445_CR37","first-page":"496","volume":"21","author":"D Brown","year":"2020","unstructured":"Brown D. A review of the PubMed PICO Tool: using evidence-based practice in Health Education. Health PromotPract. 2020;21:496\u20138.","journal-title":"Health PromotPract"},{"key":"3445_CR38","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, Cochrane Bias Methods Group; Cochrane Statistical Methods Group, et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"3445_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol. 2001;54:1046\u201355.","journal-title":"J Clin Epidemiol"},{"issue":"13\u201314","key":"3445_CR40","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1080\/15287390801985844","volume":"71","author":"E Saveleva","year":"2008","unstructured":"Saveleva E, Selinski S. Meta-analyses with binary outcomes: how many studies need to be omitted to detect a publication bias? J Toxicol Environ Health A. 2008;71(13\u201314):845\u201350. https:\/\/doi.org\/10.1080\/15287390801985844","journal-title":"J Toxicol Environ Health A"},{"key":"3445_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s10278-019-00218-y","volume":"32","author":"A Elovic","year":"2019","unstructured":"Elovic A, Pourmand A. MDCalc Medical Calculator App Review. J Digit Imaging. 2019;32:682\u20134.","journal-title":"J Digit Imaging"},{"key":"3445_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13643-019-1070-0","volume":"8","author":"L Schmidt","year":"2019","unstructured":"Schmidt L, Shokraneh F, Steinhausen K, Adams CE. Introducing RAPTOR: RevMan Parsing Tool for reviewers. Syst Rev. 2019;8:151.","journal-title":"Syst Rev"},{"issue":"7","key":"3445_CR43","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1097\/SMJ.0b013e31817a7ee4","volume":"101","author":"AJ Viera","year":"2008","unstructured":"Viera AJ. Odds ratios and risk ratios: what\u2019s the difference and why does it matter? South Med J. 2008;101(7):730\u20134. https:\/\/doi.org\/10.1097\/SMJ.0b013e31817a7ee4","journal-title":"South Med J"},{"key":"3445_CR44","first-page":"690","volume":"23","author":"BJ George","year":"2016","unstructured":"George BJ, Aban IB. An application of meta-analysis based on DerSimonian and Laird method. J NuclCardiol. 2016;23:690\u20132.","journal-title":"J NuclCardiol"},{"key":"3445_CR45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/21925682211003889","volume":"11","author":"JR Dettori","year":"2021","unstructured":"Dettori JR, Norvell DC, Chapman JR. Seeing the forest by looking at the Trees: how to interpret a Meta-analysis forest plot. Global Spine J. 2021;11:614\u20136.","journal-title":"Global Spine J"},{"key":"3445_CR46","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","volume":"11","author":"TB Huedo-Medina","year":"2006","unstructured":"Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193\u2013206.","journal-title":"Psychol Methods"},{"issue":"3","key":"3445_CR47","first-page":"61","volume":"4","author":"A Ugoni","year":"1995","unstructured":"Ugoni A, Walker BF. The Chi square test: an introduction. COMSIG Rev. 1995;4(3):61\u20134.","journal-title":"COMSIG Rev"},{"key":"3445_CR48","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4103\/IJPSYM.IJPSYM_193_19","volume":"41","author":"C Andrade","year":"2019","unstructured":"Andrade C. The P\u2009value and statistical significance: misunderstandings, explanations, challenges, and Alternatives. Indian J Psychol Med. 2019;41:210\u20135.","journal-title":"Indian J Psychol Med"},{"issue":"25","key":"3445_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3238\/arztebl.m2023.027","volume":"120","author":"K Kahnert","year":"2023","unstructured":"Kahnert K, J\u00f6rres RA, Behr J, Welte T. The diagnosis and treatment of COPD and its comorbidities. DtschArztebl Int. 2023;120(25):434\u201344. https:\/\/doi.org\/10.3238\/arztebl.m2023.027","journal-title":"DtschArztebl Int"},{"issue":"6","key":"3445_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/resp.14272","volume":"27","author":"N Murgia","year":"2022","unstructured":"Murgia N, Gambelunghe A. Occupational COPD-The most under-recognized occupational lung disease? Respirology. 2022;27(6):399\u2013410. https:\/\/doi.org\/10.1111\/resp.14272","journal-title":"Respirology"},{"issue":"4","key":"3445_CR51","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5507\/bp.2020.056","volume":"164","author":"J Zatloukal","year":"2020","unstructured":"Zatloukal J, Brat K, Neumannova K, et al. Chronic obstructive pulmonary disease - diagnosis and management of stable disease; a personalized approach to care, using the treatable traits concept based on clinical phenotypes. Position paper of the Czech Pneumological and Phthisiological Society. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020;164(4):325\u201356. https:\/\/doi.org\/10.5507\/bp.2020.056","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"3445_CR52","doi-asserted-by":"publisher","unstructured":"Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620942128. https:\/\/doi.org\/10.1177\/1753466620942128","DOI":"10.1177\/1753466620942128"},{"issue":"6","key":"3445_CR53","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/resp.14041","volume":"26","author":"M MacLeod","year":"2021","unstructured":"MacLeod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact. Respirology. 2021;26(6):532\u201351. https:\/\/doi.org\/10.1111\/resp.14041","journal-title":"Respirology"},{"issue":"1","key":"3445_CR54","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.resinv.2021.08.002","volume":"60","author":"Y Suzuki","year":"2022","unstructured":"Suzuki Y, Sato S, Sato K, Inoue S, Shibata Y. Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Investig. 2022;60(1):108\u201318. https:\/\/doi.org\/10.1016\/j.resinv.2021.08.002","journal-title":"Respir Investig"},{"issue":"12","key":"3445_CR55","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/17476348.2017.1386564","volume":"11","author":"G Caramori","year":"2017","unstructured":"Caramori G, Ruggeri P, Casolari P, Chung KF, Girbino G, Adcock IM. Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2017;11(12):955\u201367. https:\/\/doi.org\/10.1080\/17476348.2017.1386564","journal-title":"Expert Rev Respir Med"},{"key":"3445_CR56","doi-asserted-by":"publisher","first-page":"108986","DOI":"10.1016\/j.clim.2022.108986","volume":"237","author":"J Qin","year":"2022","unstructured":"Qin J, Wang G, Han D. Benefits of LAMA in patients with asthma-COPD overlap: a systematic review and meta-analysis. Clin Immunol. 2022;237:108986. https:\/\/doi.org\/10.1016\/j.clim.2022.108986","journal-title":"Clin Immunol"},{"issue":"1","key":"3445_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12890-020-1152-8","volume":"20","author":"A Koarai","year":"2020","unstructured":"Koarai A, Sugiura H, Yamada M, Ichikawa T, Fujino N, Kawayama T, Ichinose M. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):111. https:\/\/doi.org\/10.1186\/s12890-020-1152-8","journal-title":"BMC Pulm Med"},{"key":"3445_CR58","doi-asserted-by":"publisher","first-page":"101855","DOI":"10.1016\/j.pupt.2019.101855","volume":"59","author":"L Calzetta","year":"2019","unstructured":"Calzetta L, Di Marco F, Blasi F, et al. Impact of ICS\/LABA and LABA\/LAMA FDCs on functional and clinical outcomes in COPD: a network meta-analysis. PulmPharmacol Ther. 2019;59:101855. https:\/\/doi.org\/10.1016\/j.pupt.2019.101855","journal-title":"PulmPharmacol Ther"},{"issue":"1","key":"3445_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.15326\/jcopdf.2022.0332","volume":"10","author":"JM Wells","year":"2023","unstructured":"Wells JM, Criner GJ, Halpin DMG, et al. Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: Post Hoc Analysis of the IMPACT Trial. Chronic ObstrPulm Dis. 2023;10(1):33\u201345. https:\/\/doi.org\/10.15326\/jcopdf.2022.0332","journal-title":"Chronic ObstrPulm Dis"},{"key":"3445_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pupt.2015.10.005","volume":"35","author":"Y Ishiura","year":"2015","unstructured":"Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K. A comparison of the efficacy of once-daily fluticasone furoate\/vilanterole with twice-daily fluticasone propionate\/salmeterol in asthma-COPD overlap syndrome. PulmPharmacol Ther. 2015;35:28\u201333. https:\/\/doi.org\/10.1016\/j.pupt.2015.10.005","journal-title":"PulmPharmacol Ther"},{"issue":"1","key":"3445_CR61","doi-asserted-by":"publisher","first-page":"00556","DOI":"10.1183\/23120541.00556-2021","volume":"8","author":"R Dhar","year":"2022","unstructured":"Dhar R, Talwar D, Salvi S, et al. Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts\u2019 review. ERJ Open Res. 2022;8(1):00556\u20132021. https:\/\/doi.org\/10.1183\/23120541.00556-2021","journal-title":"ERJ Open Res"},{"key":"3445_CR62","doi-asserted-by":"publisher","unstructured":"Ismaila AS, Rothnie KJ, Wood RP et al. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF\/UMEC\/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study. Respir Res. 2023;24(1):229. https:\/\/doi.org\/10.1186\/s12931-023-02523-1. Erratum in: Respir Res. 2024;25(1):152. doi: 10.1186\/s12931-024-02745-x.","DOI":"10.1186\/s12931-023-02523-1"},{"key":"3445_CR63","doi-asserted-by":"publisher","unstructured":"Mar\u00edn JM, Mateos L, Rold\u00e1n J et al. Efficacy of FF\/UMEC\/VI compared with FF\/VI and UMEC\/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT. Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963021. https:\/\/doi.org\/10.1177\/1753466620963021","DOI":"10.1177\/1753466620963021"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03445-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03445-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T10:10:36Z","timestamp":1734516636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03445-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3445"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03445-4","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable as the study is totally based on the published literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}